Prostate Cancer

"It is unique given that in addition to providing prognostic information, it can serve as a marker to predict sensitivity to androgen deprivation therapy (ADT), which is the backbone of systemic therapy for men with prostate cancer," says Rana R. McKay, MD.

“I think, overall, nomograms are a really powerful tools just because there are so many different clinical variables that we consider when we talk to patients about whether to proceed with prostate biopsy,” says Eric Li, MD.

"The study demonstrated that AS rate in the MUSIC cohort, which in 2014 had been lower than in the SEER cohort, increased rapidly, from approximately 20% in 2014 to nearly 50% in 2019, whereas the SEER cohort showed only a modest increase," writes Badar M. Mian, MD.

The CDK4/6 inhibitor abemaciclib showed clinically activity in patients with heavily pretreated metastatic castration-resistant prostate cancer.

The addition of STAD did, however, improve secondary end points, including metastases rates, prostate cancer-specific mortality, and PSA failure.

The indication is restricted from the indication in the FDA supplemental New Drug Application for olaparib/abiraterone, which is for the population at-large in the BRCA–mutation positive setting.

The study is exploring the investigational N-terminal domain androgen receptor inhibitor EPI-7386 in combination with either apalutamide or abiraterone acetate.

Physicians are now using the AI-powered Unfold AI platform to work with patients on treatment selection and establishing an optimal overall management plan.

“Our results indicate that avoiding unhealthy dietary habits could be the best nutritional strategy to prevent aggressive prostate cancer,” says Adela Castelló-Pastor, PhD.

“In terms of next steps, we are collaborating with other institutions…to see how our model performs in their patient populations,” says Eric Li, MD.

“There is a lack of information regarding the prevalence and implications of [prostate cancer] in transgender women, and this highlights the crucial need for further research into prevention, detection, and treatment," says Hayley Premo.

“We were actually quite pleased with how well our model performed, particularly in the independent cohort that was separate from our training cohort,” says Eric Li, MD.

Dr Higano provides a timeline review of safety results for GnH agonists and GnRH antagonists including the recent prospective phase 3 PRONOUNCE study for prostate cancer patients with pre-existing CV disease, followed by closing thoughts on this video series.

Dr Higano explains how the use of ADT in patients with prostat ecancer may impact metabolic and cardiovascular (CV) risk factors, and shares best practices on optimizing risk assessment, mitigation, and monitoring for these factors.

A focused discussion on how ADT is used as the backbone of prostate cancer therapy across different prostate cancer risk groups and according to metastatic and castration sensitivity status.

Tia Higano, MD, FACP, provides a historical perspective on prostate cancer the use of androgen-deprivation therapy (ADT) and on prostate-specific antigen (PSA) in diagnosis and monitoring.

Chandler Park, MD, discusses lessons from the ARASENS and TITAN trials on the use of triplet vs doublet therapy in patients with metastatic hormone-sensitive prostate cancer.

“We want to minimize our negative biopsies and diagnosis of grade group 1 cancers,” says Rashid Siddiqui, MD.

The Free Coverage for Prostate Cancer Screening Amendment Act of 2023 has been processed and given a bill number.

Investigators found that the total out-of-pocket costs associated with oral therapies for prostate cancer were approximately 18 times higher compared with ADT.

"[This] could be a paradigm shift in prostate cancer,” says Eugene Shenderov, MD, PhD.

Alexandra Sokolova, MD, discusses unanswered questions and next steps with PARP inhibitors in the prostate cancer treatment paradigm.

Urologists weigh in on the challenges associated with whether, when, and how to treat these patients with prostate cancer.

Active surveillance is the preferred treatment option for men with low-risk prostate cancer and an option for some men with favorable intermediate-risk prostate cancer.

Apalutamide is approved by the FDA for the treatment of patients with non-metastatic castration-resistant prostate cancer or metastatic castration-sensitive prostate cancer.